MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
operating segment
$5,800K
Net cash (used in) /
provided by investing...
$5,245K
Canceled cashflow
$555K
Net increase in cash
and cash...
$1,761K
Canceled cashflow
$3,484K
Transaction costs from sale
of operating...
$494K
Purchases of leasehold
improvements and equipment
$61K
Proceeds from exercise of
stock options
$111K
Net income
$6,318K
Accounts payable
$2,481K
Share-based compensation
expense
$1,716K
Amortization of intangibles
$175K
Noncash lease expense
$173K
Depreciation of leasehold
improvements and equipment
$116K
Interest accretion on
deferred consideration
$114K
(recovery of) / allowance
for credit losses
$85K
Deferred consideration
liability
$41K
Non-cash financing costs
-$12K
Net cash (used in) /
provided by financing...
-$2,290K
Net cash (used in) /
provided by operating...
-$1,194K
Canceled cashflow
$111K
Canceled cashflow
$11,231K
Repurchase of common stock
$2,354K
Gain from sale of
operating segment
$4,784K
Payment of deferred
consideration
$47K
Inventories
$3,573K
Trade receivables
$3,412K
Operating lease
liabilities
-$241K
Prepaid expenses and
other assets
$169K
Deferred revenue
-$102K
Accrued expenses
-$101K
Implementation costs for cloud
computing arrangement
$30K
Customer deposits and
other
-$13K
Back
Back
Cash Flow
source: myfinsight.com
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)